The Priority Review

Approvals Brief

CHMP recommends marketing authorisation for Neuzafy

On 15 October 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Neuzafy, a filgrastim biosimilar. The applicant is CuraTeQ Biologics (Malta) Limited and Neuzafy will be available as 30 MU/0.5 ml and 48 MU/0.5 ml solutions for injection/infusion.

Primary source

EMA medicine page (CHMP opinion), October 16, 2026

Neuzafy (filgrastim): EMA CHMP opinion

Read the source ema.europa.eu

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation